Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amylyx Pharmaceuticals (AMLX) Total Current Liabilities: 2021-2024

Historic Total Current Liabilities for Amylyx Pharmaceuticals (AMLX) over the last 4 years, with Dec 2024 value amounting to $28.4 million.

  • Amylyx Pharmaceuticals' Total Current Liabilities fell 52.16% to $25.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $25.8 million, marking a year-over-year decrease of 52.16%. This contributed to the annual value of $28.4 million for FY2024, which is 65.38% down from last year.
  • Latest data reveals that Amylyx Pharmaceuticals reported Total Current Liabilities of $28.4 million as of FY2024, which was down 65.38% from $82.0 million recorded in FY2023.
  • In the past 5 years, Amylyx Pharmaceuticals' Total Current Liabilities ranged from a high of $82.0 million in FY2023 and a low of $17.4 million during FY2021.
  • For the 3-year period, Amylyx Pharmaceuticals' Total Current Liabilities averaged around $52.4 million, with its median value being $46.6 million (2022).
  • In the last 5 years, Amylyx Pharmaceuticals' Total Current Liabilities soared by 167.93% in 2022 and then tumbled by 65.38% in 2024.
  • Amylyx Pharmaceuticals' Total Current Liabilities (Yearly) stood at $17.4 million in 2021, then skyrocketed by 167.93% to $46.6 million in 2022, then skyrocketed by 76.02% to $82.0 million in 2023, then plummeted by 65.38% to $28.4 million in 2024.